Continuous-Flow GLP-1 Peptide Synthesis Plant Model
Underwrite automated continuous-flow solid-phase peptide synthesizers producing 12,000 kg/year of active GLP-1 (Semaglutide/Tirzepatide) APIs with 95% reduced solvent consumption. Model pharma off-take supply agreements ($3,800/kg), and 20-yr IRR.
1. Capacity & Unit Economics
2. Financial Returns & Yield
12,000kg/YR GLP-1 APIAnnual Net EBITDA
$0 / yr
20-Yr Project IRR
0.0%
Gross Revenue
$0 / yr
Total CapEx
$0
Annual OpEx
$0 / yr